Detalles de la búsqueda
1.
Ramucirumab in combination with pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma: a single-centre, phase 1/2 trial.
Lancet Oncol
; 2024 Jun 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-38851207
2.
Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial.
Lancet Oncol
; 20(9): 1295-1305, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31351869
3.
Pazopanib plus cetuximab in recurrent or metastatic head and neck squamous cell carcinoma: an open-label, phase 1b and expansion study.
Lancet Oncol
; 19(8): 1082-1093, 2018 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-30001987
4.
A phase 2 trial of induction nab-paclitaxel and cetuximab given with cisplatin and 5-fluorouracil followed by concurrent cisplatin and radiation for locally advanced squamous cell carcinoma of the head and neck.
Cancer
; 119(4): 766-73, 2013 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-22991252
5.
Cisplatin versus cetuximab given concurrently with definitive radiation therapy for locally advanced head and neck squamous cell carcinoma.
Oncology
; 85(5): 290-6, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-24217231
6.
Hearing Outcomes in a Deintensification Trial of Adjuvant Therapy for HPV-Related Oropharyngeal Squamous Cell Carcinoma.
Otolaryngol Head Neck Surg
; 168(5): 1089-1096, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36939390
7.
Multidimensional biomarker predicts disease control in response to immunotherapy in recurrent or metastatic head and neck squamous-cell carcinoma.
J Cancer Res Clin Oncol
; 149(15): 14125-14136, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37552307
8.
Preexisting tumor-resident T cells with cytotoxic potential associate with response to neoadjuvant anti-PD-1 in head and neck cancer.
Sci Immunol
; 8(87): eadf4968, 2023 09 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37683037
9.
The Potential for Selective Cyclin-Dependent Kinase 4/6 Inhibition in the Therapy for Head and Neck Squamous Cell Carcinoma.
Cancer J
; 28(5): 377-380, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36165726
10.
T cell subtype profiling measures exhaustion and predicts anti-PD-1 response.
Sci Rep
; 12(1): 1342, 2022 01 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-35079117
11.
Palbociclib and cetuximab in cetuximab-resistant human papillomavirus-related oropharynx squamous-cell carcinoma: A multicenter phase 2 trial.
Oral Oncol
; 114: 105164, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33465681
12.
Genomic and neoantigen evolution from primary tumor to first metastases in head and neck squamous cell carcinoma.
Oncotarget
; 12(6): 534-548, 2021 Mar 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-33796222
13.
Nanoparticle albumin-bound paclitaxel with cetuximab and carboplatin as first-line therapy for recurrent or metastatic head and neck cancer: A single-arm, multicenter, phase 2 trial.
Oral Oncol
; 115: 105173, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33548860
14.
Phase II study of dacarbazine given with modern prophylactic anti-emetics and growth factor support to patients with metastatic, resistant soft tissue, and bone sarcoma.
Rare Tumors
; 13: 20363613211052498, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34646430
15.
Palbociclib and cetuximab compared with placebo and cetuximab in platinum-resistant, cetuximab-naïve, human papillomavirus-unrelated recurrent or metastatic head and neck squamous cell carcinoma: A double-blind, randomized, phase 2 trial.
Oral Oncol
; 115: 105192, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33571736
16.
nab-Paclitaxel and cisplatin followed by cisplatin and radiation (Arm 1) and nab-paclitaxel followed by cetuximab and radiation (Arm 2) for locally advanced head and neck squamous-cell carcinoma: a multicenter, non-randomized phase 2 trial.
Med Oncol
; 38(4): 35, 2021 Mar 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33683482
17.
Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial.
Clin Cancer Res
; 26(19): 5140-5152, 2020 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32665297
18.
Prospective assessment of the clinical benefit of a tailored cancer gene set built on a next-generation sequencing platform in patients with recurrent or metastatic head and neck cancer.
Med Oncol
; 37(2): 12, 2019 Dec 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-31865465
19.
nab-Paclitaxel-based induction chemotherapy followed by cisplatin and radiation therapy for human papillomavirus-unrelated head and neck squamous-cell carcinoma.
Med Oncol
; 36(11): 93, 2019 Oct 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31595355
20.
Dynamic host immune response in virus-associated cancers.
Commun Biol
; 2: 109, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30911684